Wall Street analyst estimates for KALA BIO, Inc. (KALA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 6 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (1-5) | 0.27 |
Valuation Ratios
| Price / Book | 0.00 |
| EV / EBITDA | -1.09 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $6.1M | $6.4M | $11.2M | $3.9M | 0 | 0 | 0 |
| Cost of Revenue | $297000 | $643000 | $955000 | $2.8M | $3.2M | $4.1M | $2.6M | $303000 | $259000 | 0 |
| Gross Profit | -$297000 | -$643000 | -$955000 | $3.2M | $3.2M | $7.1M | $1.3M | -$303000 | -$259000 | 0 |
| Research & Development | $25.0M | $29.0M | $29.3M | $27.0M | $18.4M | $11.5M | $17.7M | $18.6M | $21.8M | $18.8M |
| Selling, General & Admin | $7.3M | $10.2M | $34.5M | $64.5M | $81.1M | $105.1M | $65.0M | $20.3M | $18.3M | $23.6M |
| Operating Expenses | $32.4M | $39.2M | $63.8M | $91.5M | $99.4M | $116.6M | $82.7M | $38.9M | $40.2M | $39.2M |
| Operating Income | -$32.7M | -$39.9M | -$64.7M | -$88.2M | -$96.2M | -$109.4M | -$81.4M | -$39.2M | -$40.4M | -$39.2M |
| EBITDA | -$32.4M | -$39.2M | -$63.8M | -$85.6M | -$93.4M | -$132.0M | -$36.7M | -$36.1M | -$32.5M | -$23.4M |
| Interest Expense | $767000 | $1.0M | $3.3M | $8.5M | $8.6M | $8.4M | $7.3M | $5.8M | $5.8M | $3.3M |
| Pre-tax Income | -$33.2M | -$42.2M | -$66.7M | -$94.3M | -$104.3M | -$142.6M | -$44.8M | -$42.2M | -$38.5M | -$27.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$33.2M | -$42.2M | -$66.7M | -$94.3M | -$104.3M | -$142.6M | -$44.8M | -$42.2M | -$38.5M | -$27.0M |
| EPS | $-95.95 | $-99.20 | $-124.73 | $-138.00 | $-99.50 | $-108.32 | $-1474.00 | $-867.50 | $-507.50 | $-165.50 |
| EPS (Diluted) | $-95.95 | $-99.20 | $-124.73 | $-138.00 | $-99.50 | $-108.32 | $-1474.00 | $-867.50 | $-507.50 | $-165.50 |
| Shares Outstanding (Diluted) | $345667 | $425499 | $535078 | $684195 | $1.0M | $1.3M | $30412 | $48640 | $75920 | $162965 |
Price
| Price | $0.52 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABP · AIM · CANF · ENSC · IBO · KTTA · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KALA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks